Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash & Equivalents: 2019-2025

Historic Cash & Equivalents for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $643.0 million.

  • BridgeBio Pharma's Cash & Equivalents rose 141.42% to $643.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $643.0 million, marking a year-over-year increase of 141.42%. This contributed to the annual value of $681.1 million for FY2024, which is 81.18% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Cash & Equivalents of $643.0 million as of Q3 2025, which was down 14.15% from $749.0 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Cash & Equivalents registered a high of $749.0 million during Q2 2025, and its lowest value of $180.3 million during Q3 2021.
  • For the 3-year period, BridgeBio Pharma's Cash & Equivalents averaged around $486.7 million, with its median value being $475.2 million (2024).
  • Per our database at Business Quant, BridgeBio Pharma's Cash & Equivalents plummeted by 50.85% in 2021 and then skyrocketed by 167.95% in 2022.
  • BridgeBio Pharma's Cash & Equivalents (Quarterly) stood at $393.8 million in 2021, then dropped by 4.34% to $376.7 million in 2022, then declined by 0.20% to $375.9 million in 2023, then skyrocketed by 81.18% to $681.1 million in 2024, then soared by 141.42% to $643.0 million in 2025.
  • Its Cash & Equivalents was $643.0 million in Q3 2025, compared to $749.0 million in Q2 2025 and $540.6 million in Q1 2025.